Shares of Puma Biotechnology PBYI have tanked 9.6% in the past month, reflecting the growing investor concern regarding the ...

In a surprising turn of events, Puma's shares surged over 22% on August 25, despite a year of poor performance and economic headwinds. However, there's a reason behind this unexpected change in the ...

PUMA (XTRA:PUM) has caught investors’ attention after a mixed performance, with the stock showing gains over the past month ...

Mike Ashley's Frasers is the second largest shareholder of Puma after Anta Sports, which holds a 29 percent stake in the ...

Ratings for Puma Biotechnology (NASDAQ:PBYI) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings ...

Puma faces significant headwinds: Weak US/China demand, leadership turnover, and a 41% stock drop since my last article. Despite challenges, I see potential for a long-term turnaround, especially with ...

Shares of Puma Biotechnology PBYI have rallied 35.3% in the past six months against the industry’s decline of 9.2%. The company’s sole marketed product, Nerlynx (neratinib), is approved for treating ...

Puma shares slumped on Thursday as the German apparel maker’s preliminary fourth-quarter numbers disappointed analysts. Puma reported fourth-quarter revenue growth, at constant currencies, of 9.8% to ...

Wondering whether PUMA shares offer value at today's price, or if the risks still outweigh the potential upside? This article is here to unpack what the current market is implying. The stock last ...

Shares of Puma tumbled to a near nine-year low on Wednesday after the German sportswear group warned that geopolitical tensions and trade uncertainty would contribute to another year of weak growth.